Karuna Therapeutics Reports Fourth Quarter and End of Fiscal 2020 Financial Results and General Business Update

Karuna Therapeutics Reports Fourth Quarter and End of Fiscal 2020 Financial Results and General Business Update

Two phase 3 trials, EMERGENT-2 and EMERGENT-4, initiated the evaluation of KarXT for the treatment of psychosis in adults with schizophrenia

Results of the Phase 2 EMERGENT-1 clinical trial of KarXT in schizophrenia published in the New England Journal of Medicine

The first two cohorts of the phase 1b trial in healthy elderly volunteers have been completed, with the results of cohort 3 expected in the second quarter of 2021

Exclusivity of patents granted on KarXT co-formulation compositions until 2039

$ 322.3 million in cash, cash equivalents and available-for-sale investments are expected to fund several potential milestones, including the completion of the EMERGENT program and subsequent New Drug Application (NDA)…

Read Additional From Source

Copyright @ finance.yahoo.com

News Highlights Finance

  • Headline: Karuna Therapeutics Reports Fourth Quarter and End of Fiscal 2020 Financial Results and General Business Update
  • Check all news and articles from the Finance news updates.
Disclaimer: If you need to update/edit/remove this news or article then please contact our support team.
For Latest Updates Follow us on Google News
Bollyinside - US Local News & Breaking News Stories
Logo
Compare items
  • Total (0)
Compare
0